Tegsedi (Inotersen) for amyloidosis

Overview
Tegsedi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve damage resulting from hereditary transthyretin-mediated (hATTR) amyloidosis. Tegsedi is also referred to by its drug name, inotersen.

Tegsedi is a member of a class of drugs called antisense oligonucleotides (ASO). Tegsedi is believed to work by inhibiting the creation of amyloid proteins in cells.

How do I take it?
Prescribing information states that Tegsedi is given as a subcutaneous injection (under your skin) by a health care professional. Tegsedi is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Side effects
The FDA-approved label for Tegsedi lists common side effects that include injection site reactions, nausea, headache, fatigue, thrombocytopenia (low blood platelet count), and fever.

Serious side effects listed for Tegsedi include stroke, nerve inflammation, liver dysfunction, and vitamin A deficiency.

For more details about this treatment, visit:
Tegsedi — Akcea
Tegsedi — Akcea Tegsedi patient brochure